about
Evaluation of a novel type of imaging probe based on a recombinant bivalent mini-antibody construct for detection of CD44v6-expressing squamous cell carcinoma.The novel HSP90 inhibitor AT13387 potentiates radiation effects in squamous cell carcinoma and adenocarcinoma cells.Characterization of CD44 variant expression in head and neck squamous cell carcinomas.In vivo characterization of the novel CD44v6-targeting Fab fragment AbD15179 for molecular imaging of squamous cell carcinoma: a dual-isotope study.A real-time in vitro assay as a potential predictor of in vivo tumor imaging properties.Choice of labeling and cell line influences interactions between the Fab fragment AbD15179 and its target antigen CD44v6.Determination of receptor protein binding site specificity and relative binding strength using a time-resolved competition assay.A novel CD44v6 targeting antibody fragment with improved tumor-to-blood ratio.Improved tumor-to-organ ratios of a novel 67Ga-human epidermal growth factor radionuclide conjugate with preadministered antiepidermal growth factor receptor affibody molecules.CD44v6-Targeted Imaging of Head and Neck Squamous Cell Carcinoma: Antibody-Based Approaches.HSP90 inhibition in angiosarcoma.The effect of a dimeric Affibody molecule (ZEGFR:1907)2 targeting EGFR in combination with radiation in colon cancer cell lines.Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy.The MDM2/MDMX-p53 Antagonist PM2 Radiosensitizes Wild-Type p53 TumorsThe Stapled Peptide PM2 Stabilizes p53 Levels and Radiosensitizes Wild-Type p53 Cancer CellsThe HSP90 inhibitor onalespib potentiates 177Lu‑DOTATATE therapy in neuroendocrine tumor cellsThe HSP90 inhibitor Onalespib exerts synergistic anti-cancer effects when combined with radiotherapy: an in vitro and in vivo approachThe radiosensitizer Onalespib increases complete remission in 177Lu-DOTATATE-treated mice bearing neuroendocrine tumor xenografts
P50
Q36498107-1661AF13-18C0-41D2-953A-076A39D3640AQ36546425-2DF529FD-782D-4519-9E99-18AA58DC96B0Q37666502-44DCB861-706A-40AF-B88B-F4B051FED110Q37684670-B3562553-0811-4D4C-8AED-3D94D82E7D36Q38809202-1064CAF5-79E4-4E2B-BA23-54B3DC72967BQ39051899-D9F675A3-0C5B-4251-B41E-B0639B6741BDQ39149961-4BB48910-984E-48AC-95F8-C5FB958E504EQ39401218-3964F41D-4AC1-49A8-AC71-F2F6DA50FB7BQ39491767-772A2939-6161-46C9-AF7C-9364E2F089E8Q43376023-64BF6324-9139-47C2-A0B6-C26D7B4BA210Q47917132-0B2577B5-DD4E-40D7-A7C8-3422FEBDF21EQ54564446-EB224A2D-EB70-41C0-AF34-EBC1B06CC7F6Q55309145-615D88B8-1D26-4192-9D02-53C7136B77A9Q60666263-CB439EF1-9BCC-4A26-B735-F0C091C1FF57Q90734672-0282A89C-03EB-4992-B5C6-32CEB6399FE1Q90868547-AF2EDC4E-37BE-4A80-8725-07C0D7A63001Q91555704-33E7C843-1088-410D-8B7E-BDFDF3DF9867Q92484548-D54C5657-78EF-4C82-83CE-51E59E07087F
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Diana Spiegelberg
@ast
Diana Spiegelberg
@en
Diana Spiegelberg
@es
Diana Spiegelberg
@nl
Diana Spiegelberg
@sl
type
label
Diana Spiegelberg
@ast
Diana Spiegelberg
@en
Diana Spiegelberg
@es
Diana Spiegelberg
@nl
Diana Spiegelberg
@sl
prefLabel
Diana Spiegelberg
@ast
Diana Spiegelberg
@en
Diana Spiegelberg
@es
Diana Spiegelberg
@nl
Diana Spiegelberg
@sl
P214
P106
P21
P214
P31
P496
0000-0002-1509-2142
P735
P7859
viaf-315728074